

# **Engaging in the EU Regulatory Network: Member State Journeys**

Momir Radulović, MPharm 19<sup>th</sup> March 2021

### Slovenia













Population: 2,1 mio

Health expenditure per capita: 2186 PPP € (EU 27: 2552

PPP €)

Life expectancy: 81,6 yrs

- The first Green Country in the World
- Slovenia the hottest destination in 2019 by Virtuoso
- European Region of Gastronomy 2021



- Source: The Health Insurance Institute of Slovenia Annual Report 2020; Available at: https://api.zzzs.si/ZZZS/info/egradiva.nsf/0/a998991f0f548b4bc125868c0040ba61/\$FILE/Letno%20poro%C4%8Dilo%20ZZZS 2.3.2020.pdf
- Source: Eurostat, March 2021

# AGENCY FOR MEDICINAL PRODUCTS AND MEDICAL DEVICES OF THE REPUBLIC OF SLOVENIA
















# Contribution to the EU network Centralized procedures













Product	Start of procedure	JAZMP
Zalasta	2006	Rapp
Grepid	2008	Rapp
Clopidogrel Teva	2008	Rapp
Clopidogrel Apotex	2008	Rapp
Clopidogrel Ratiopharm	2014	Rapp
Clopidogrel / Acetylsalicylic acid Mylan	2018	Rapp



Product	Start of procedure	JAZMP
Fingolimod Mylan	23. 5. 2019	Rapp
Fingolimod Accord	23. 5. 2019	Peer review
Fampridine Accord	15. 8. 2019	Rapp
Conf.	2020	Rapp
Enyglid	Brexit redistribution	Rapp
Cetrotide	Brexit redistribution	Co-Rapp
Ledaga	Brexit redistribution	Rapp
Conf.	2020	MNAT
Conf.	2021	MNAT

## **Contribution to the EU network MRP/DCP New applications**














#### STARTED Procedures – MRP/DCP per RMS


New MA - SI as RMS in MRP/DCP

- 2004 – 2018: 105

- 2019 - 2021: 39



Total 310 MRP and 1006 DCP (regarding 615 and 1996 products respectively)



Total 318 MRP and 1062 DCP (regarding 584 and 2145 products respectively)

• Source: CMDH Statistics accessed at <a href="https://www.hma.eu/87.html">https://www.hma.eu/87.html</a>

## **Contribution to the EU network Surveillance 2019**













#### **Inspection Division**

EMA and EDQM GMP inspections: 4

local GMP inspections 20 (including MRA)

Third countries GMP inspections

GDP inspections: 21

**GVP: 12** 



#### Pharmacovigilance

EMA GMP inspections: 4

PSUSA Lead MS: 9 substances (10 in total before 2019)

Signal detection: 9 substances (10 in total before 2019)

3172 new reports on suspected ADRs (1526 reports/mio)

1068 follow-up reports

 more than 150 of adverse reaction reports per 100.000 inhabitants in 2019



### How the future will look like?














### **Precision Medicine**





### **Stronger network**
















Cooperation (MNAT)

Balance

between

• Expertise enhancement

Knowledge & network



• Expansion of capacity

• Spreading the workload

countries

**Growth of EU** network

More flexible EU network

